Search results | bladder cancer

Reports

Bladder Cancer Partnering

The Bladder Cancer Partnering provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Spectrum Pharmaceuticals: Partnering activity 2009-2014

Spectrum Pharmaceuticals, headquartered in the United States, showcases in the top 50 big biotech companies.

Spectrum Pharmaceuticals: Where partnering IS the business model

Spectrum Pharmaceuticals is a biotechnology company providing key oncology and haematology products for patients around the world.

Ipsen: Developing niche products to increase life expectancy

Ipsen is a French specialty pharmaceutical company developing products to increase life expectancy.

Endo Pharmaceuticals: Blending internal R&D, licensing and M&A’s

Endo Pharmaceuticals is a top 50 pharma company specialising in brand pharmaceuticals for the treatment of pain, urology, oncology, CNS and derma products.

Watson sets aside $6 billion to buy brand-name drug assets

Watson‘s Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker.

Events

Sorry, your search returned no results.


Deals

TARIS Biomedical pharma alliances with AstraZeneca for bladder cancer treatment

TARIS Biomedical pharma alliances with AstraZeneca, a big pharma company,to evaluate novel treatments for bladder cancer

Abbott Molecular expands agreement with GSK to include development of companion diagnostic test for additional cancer immunotherapy antigen

Abbott will expand its existing agreement with GlaxoSmithKline Biologicals (GSK) to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program

Spectrum Pharmaceuticals announces m&a deal with Allergan to reacquire rights for apaziquone

Big biotech, Spectrum Pharmaceuticals, is in a m&a deal with Allergan

Watson sets aside $6 billion to buy brand-name drug assets

Watson‘s Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational” purchase as he reshapes the generic-drug maker.

Merck forms pharma partnering with Amgen, Pfizer and Incyte

Merck  has signed three separate pharma partnering clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy.